Dystrogen Therapeutics is a clinical-stage life sciences company committed to developing personalized therapies for rare genetic diseases. The company focus on treating patients with rare diseases such as Duchenne muscular dystrophy.
The company was founded based on the pioneering work on chimeric cells therapy for transplantation tolerance, developed by Professor Maria Siemionow MD, PhD, a world renowned scientist and surgeon who led a team of surgeons that performed the first near-total face transplantation in the United States. Our technologies are developed in collaboration with the University of Illinois.

• Press Releases:
  • January 23, 2023: Dystrogen Therapeutics Corp Announces Presentation of Abstracts at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference
  • September 26, 2022: Dystrogen Therapeutics Investigational Chimeric Cell Therapy DT-DEC01 for Duchenne Muscular Dystrophy Demonstrates Clinically Significant Functional and Biomarker Improvements
  • April 7, 2022: Dystrogen Therapeutics Investigational Chimeric Cell Therapy DT-DEC01 for the Treatment of Duchene Muscular Dystrophy Shows Safety and Functional Improvements
  • January 4, 2022: Dystrogen Therapeutics Announces First in Man Dosing of Novel Chimeric Cell Therapy for Duchenne Muscular Dystrophy and Reports 6-week Clinical Outcomes
  • August 18, 2020: FDA has granted Dystrogen Therapeutics Rare Pediatric Disease (RPD) Designation and Orphan Drug Designation for the company’s product candidate: Dystrophin Expressing Chimeric (DEC) Cell Therapy Dystrophin Expressing Chimeric DT-DEC01
  • November 05, 2019: /PRNewswire/ Dystrogen Therapeutics announces that treatment with Dystrophin Expressing Chimeric (DEC) Cells improves cardiac function in preclinical Duchenne’s study
  • September 12, 2019: UIC today – Human ‘chimeric’ cells restore crucial protein in Duchenne muscular dystrophy
  • June 6, 2019: The New York Times – Your Surgeon’s Childhood Hobbies May Affect Your Health
  • April 26, 2019: Positive Opinion from Ethics Committee to perform a First-in-Human trial (pdf) – Duchenne therapy

• Conference:
  • 2023 Muscular Dystrophy Association Clinical & Scientific Conference
    March 19-22, 2023 in Dallas, Texas:
    • „Assessment of Preliminary Safety and Efficacy of DT-DEC01 Therapy at 12-months after administration to in Duchenne Muscular Dystrophy Patients”
    • „Electromyography as an Efficacy Biomarker with Improvement in Motor Unit Potentials after DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients”
    • „Prevalence of Anti-HLA Antibodies in Duchenne Muscular Dystrophy Patients at Screening Visit and After Intra-bone Administration of DT-DEC01 Therapy”
  •  2019 The Muscular Dystrophy Association (MDA) Clinical and Scientific Conference
    April 13-17 2019, at the Hyatt Regency, Orlando.At the conference was presented the data from our pre-clinical studies related to systemic delivery of dystrophin expressing chimeric cells “DEC” and how they circumvent the immune response and improve a number of functional characteristics. The new results confirm the feasibility and efficacy of chimeric cell therapy and represent a novel satellite cell-based approach for the treatment of DMD.
    Conference poster: Systemically delivering dystrophin expressing chimeric (DEC) cells circumvents an immune response and improves various functional characteristics.(pdf)

Dystrogen presentation – Duchenne therapy (pdf)

Investor Relations Contacts: investors@dystrogen.com

Marta Osęka
Vice President of Business Development and Investor Relations
oseka@dystrogen.com